SKIN earnings analysis
What we found in SKIN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
SkinHealth Systems reported Q1 2026 results with revenue of $64.9 million, down from $69.6 million in Q1 2025, reflecting a 6.7% year-over-year decline. Diluted EPS improved to -$0.05 from -$0.08 a year prior, showing a positive trend despite missing revenue expectations by 2.1%.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline Year-Over-Year
- Revenue decreased to $64.9 million from $69.6 million, a decline of 6.7% compared to Q1 2025.
- Better EPS Performance Than Expected
- Diluted EPS improved to -$0.05 from -$0.08 year-over-year, exceeding estimates of -$0.08.
- Reduced Operating Expenses
- Total operating expenses for Q1 2026 were $46.2 million, down from $60.6 million in Q1 2025, a decrease of 23.8%.
- Higher Gross Margin Relative to Sales
- Gross profit was $44.4 million with a gross margin of 68.5%, down slightly from 69.8% a year prior.
- Post-Repurchase Cash Position
- Cash, cash equivalents, and restricted cash decreased to $204.4 million, down from $232.7 million at the beginning of the quarter.
- Management Expresses Commitment to Operational Improvements
- Management has highlighted efforts to optimize product costs alongside facing macroeconomic challenges.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Sales Decline in Delivery Systems and Consumables
- Delivery Systems revenue dropped by 8.3% and Consumables by 6.1% year-over-year, affecting overall financial performance.
- Increased Interest Expense
- Interest expense surged to $6.3 million from $2.5 million, an increase of 154% compared to Q1 2025.
- Pressure from Macroeconomic Factors
- Management noted ongoing global economic conditions negatively impacting sales and customer spending.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.05
- Gross margin
- 68.5%
- Segment
- Delivery Systems: $18.5M; Consumables: $46.4M
What they said about what is next.
2026 revenue guidance reflects continued pressure on device sales.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 12, 2026
- BeautyHealth (SKIN) reports Q4 revenue of $82,400,000 (beat consensus $78,138,140) and GAAP diluted EPS of $(0.06) (in line with estimate). Full-year revenue declined to $301,000,000 in 2025 from $334,000,000 in 2024,…
- 10-Q · November 6, 2025
- The Beauty Health Company reported Q3 net sales of $70,655 (in thousands) and GAAP diluted loss per share of $(0.09). Gross profit expanded to $45,634 (64.6% gross margin) and operating loss narrowed to $(6,242) versus…
- 10-K · March 12, 2025
- The 10-K frames The Beauty Health Company as a ‘‘medtech meets beauty’’ platform centered on Hydrafacial’s Syndeo Delivery System and a razor/razor‑blade consumables model, with an esthetician-focused go‑to‑market and…
- 10-Q · November 12, 2024
- HydraFacial reported Q3 net sales of $78,802,000 and diluted EPS of $(0.15). Gross profit improved to $40,649,000 (51.6% margin) driven by a recovery in consumables, while the company remained unprofitable at the…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SKIN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever